Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) EBT (2016 - 2025)

Kiora Pharmaceuticals' EBT history spans 11 years, with the latest figure at -$7.2 million for Q4 2025.

  • For Q4 2025, EBT fell 232.01% year-over-year to -$7.2 million; the TTM value through Dec 2025 reached -$12.1 million, down 314.1%, while the annual FY2025 figure was -$12.1 million, 314.1% down from the prior year.
  • EBT reached -$7.2 million in Q4 2025 per KPRX's latest filing, down from -$616323.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $13.5 million in Q1 2024 to a low of -$14.4 million in Q4 2021.
  • Average EBT over 5 years is -$2.5 million, with a median of -$2.4 million recorded in 2022.
  • Peak YoY movement for EBT: tumbled 1126.36% in 2021, then surged 801.91% in 2024.
  • A 5-year view of EBT shows it stood at -$14.4 million in 2021, then skyrocketed by 74.26% to -$3.7 million in 2022, then surged by 43.87% to -$2.1 million in 2023, then dropped by 3.82% to -$2.2 million in 2024, then tumbled by 232.01% to -$7.2 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's EBT are -$7.2 million (Q4 2025), -$616323.0 (Q3 2025), and -$2.3 million (Q2 2025).